trial

A Phase 1 Safety Study in Adults With Schizophrenia

NCTId NCT02804568
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 42 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2016-06
Primary completion
2016-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ALKS 3831

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
David McDonnell, MDStudy Director

Sites

3 total
Little Rock, United StatesClementon, United StatesDayton, United States

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE1
Primary Completion Date
2016-08
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 3831
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David McDonnell, MD
person